Multiple sclerosis as a biological and clinical continuum: from risk factors to the early stages of disease

• by Ana Belén Caminero, María Luisa Martínez Ginés, Montserrat Gómez Gutiérrez, Inmaculada García Castañón

• May 28, 2026

Cognitive Function and Fatigue in Stable Multiple Sclerosis: EDSS and MRI Assessments Surpass Serum Biomarkers

• by Deborah K. Erhart, Luisa T. Balz, Roland Opfer, Lothar Spies, Franziska Bachhuber, Ioannis Vardakas, Daniela Taranu, Stefanie Jung, Tanja Fangerau, Makbule Senel, Kornelia Kreiser, Ingo Uttner, Dorothée Lulé, Hayrettin Tumani

• April 17, 2026

CSF Proteomics Identifies New Biomarkers for Multiple Sclerosis

Large-cohort CSF proteomics from the Mann Lab identifies a 22-protein panel distinguishing MS from related diseases

• March 11, 2026

• 3 min

Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort

• by Jakob Stögbauer, Moritz Bewarder, Linda Groß, Lorenz Thurner, Klaus Fassbender, Rebecca Urschel, Einar A. Høgestøl, Gro O. Nygaard, Hanne F. Harbo, Olaf Stüve, Marc Pawlitzki, Sven G. Meuth, Martina Sester, Sergiu Groppa, Mathias Fousse

• May 12, 2026